UPDATE: Piper Jaffray Starts Moderna (MRNA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $229.07 +3.73%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 13
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 13
Join SI Premium – FREE
(Updated - January 2, 2019 3:30 AM EST)
(updated to correct company name)
Piper Jaffray analyst Edward Tenthoff initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $15.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1 call to 1 put into quarter results
- Moderna (MRNA) January 210 and 240 calls active amid wide price movement
- Moderna stock rises on latest cancer vaccine data publication
Create E-mail Alert Related Categories
New CoverageRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
